Aims: To evaluate and compare the recall rate in congenital hypothyroidism screening project in Isfahan, first using an approach involving measures of both TSH and T4 and then using TSH alone. Methods: From June 2002 to January 2005, serum TSH and T4 level of referred neonates were measured at 3rd to 7th day of birth through venous sampling. If neonates’ serum TSH was >20 mIU/l or T4 was <6.5 µg/dl by the first protocol, or TSH was >20 mIU/l by the second protocol, they were recalled. TSH and T4 were measured using an immunoradiometric assay and radioimmunoassay, respectively. Neonates with TSH > 10 and T4 < 6.5 on their second measurement were considered as congenitally hypothyroid. Results: Serum T4 and TSH of 29,425 neonates by first and 57,235 neonates by second recall approach were measured. Recall rate was higher in the first protocol (2.2% vs. 0.6%, p < 0.05). Most of the recalled neonates in the first protocol were recalled for low T4 level (p < 0.05). The prevalence of CH was 1 in 350 livebirths. Conclusion: Although the recall rate was in the acceptable range by either approach, the TSH alone protocol seems to be a more sensitive and practical approach with the least recall burden and considering the high prevalence of CH in our region merit adaptation of widespread screening for CH using TSH measurements from heel stab blood spotted on filter paper.

Keywords:
Congenital hypothyroidism, Thyroxin, Thyroid-stimulating hormone
1.
Wu LL, Sazali BS, Adeeb N, Khalid BA: Congenital hypothyroid screening using cord blood TSH. Singapore Med J 1999;40:23–26.
2.
Harris Pl, Dreyfus NG: Newborn thyroid screening in a municipal hospital. Am J Dis Child 1982;136:248–250.
3.
Fisher DA: Disorders of the thyroid in the newborn and infant; in Sperling MA (ed): Pediatric Endocrinology, ed 1. Philadelphia, Saunders, 1996, pp 51–70.
4.
Screening for congenital hypothyroidism [editorial]. Thyroid 2003;13:87–94.
5.
Hung E: Thyroid disorders of infancy and childhood; in Becker KL (ed): Principles and Practice of Endocrinology and Metabolism, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 463–471.
6.
Klein RZ, Mitchell ML: Hypothyroidism in infants and children; in Braverman LE (ed): The Thyroid, ed 8. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 973–988.
7.
Frank JE, Faix JE, Hermos RJ, Mullaney DA, Mitchell ML, et al: Low birth weight infant: effects on neonatal hypothyroidism screening. J Pediatr 1996;128:548–554.
8.
Ordookhani A, Mirmiran P, Hedayati M, Hajipour R. Azizi F: Screening for congenital hypothyroidism in Tehran and Damavand: an interim report on descriptive and etiologic findings, 1998–2001. IJEM 2002;4:153–160.
9.
Karamizadeh Z, Amirhakimi GH: Incidence of congenital hypothyroidism in Fars Province, Iran. Iranian J Med Sci 1992;17:78–80.
10.
Dluholucky S, Hornova V, Bucek M, Langer P: Studies on congenital hypothyroidism and results of three and half years of compulsory screening program in Slovak, Socialist Republic. Endocrinol Exp 1998;23:125–135.
11.
Berardi R, Baracchi MR, Borgogni P, Margollicci MA, Mettei R, Fois A: Results of a screening project for congenital hypothyroidism in 4 years of experience. Pediatr Med Chir 1982;4:657–660.
12.
Ordoukhani A, Mirsaiid Ghazi AA, Hajipour R, Mirmiran P, Azizi F: Screening for congenital hypothyroidism: before and after iodine supplementation in Iran. IJEM 2002;2:93–98.
13.
Chanoine JP, Boulvain M, Bourdoux P, Pardou A, Van Thi HV, Ermans AM, Delange F: Increased recall rate at screening for congenital hypothyroidism in breast fed infants born to iodine overloaded mothers. Arch Dis Child 1988;63:1207–1210.
14.
Walfish PG: Evaluation of three thyroid-function screening tests for detecting neonatal hypothyroidism. Lancet 1976;i:1208–1210.
15.
Fagela-Domingo C, Padilla CD, Cutiongco EM: Screening for congenital hypothyroidism (CH) among Filipino newborn infants. Philippine Newborn Screening Study Group. Southeast Asian J Trop Med Publ Health 1999;30(suppl 2):20–22.
16.
Moslinger D, Frisch H, Strobl W, Stockler-Ipsiroglu S: Neonatal screening for congenital hypothyroidism. Acta Med Austr 1997;24:162–164.
17.
Mengreli C, Yiannakou L, Pantelakis S: The screening program for congenital hypothyroidism in Greece: evidence of iodine deficiency in some areas in the country. Acta Paediatr 1994;(suppl 394):47–51.
18.
Peter F, Blatniczky L, Kovacs L, Tar A: Experience with neonatal screening for congenital hypothyroidism in Hungary. Endocrinol Exp 1989;23:143–151.
19.
Yordam N, Calikoglu AS, Hatun S, Kandemir N, Oguz H, Tezio T, Ozalp I: Screening for congenital hypothyroidism in Turkey. Eur J Pediatr 1995;154:614–618.
20.
Mikelsaar RV, Zordania R, Viikmaa M, Kudrjavtseva G: Neonatal screening for congenital hypothyroidism in Estonia. J Med Screen 1998;5:20–21.
21.
Mahachoklertwattana P, Phuapradit W, Siripoonya P, Charoenpol O, Thuvasethakul P, Rajatanavin R: Five year thyrotropin screening for congenital hypothyroidism in Ramathibodi Hospital. J Med Assoc Thai 1999;82(suppl 1):S27–39.
22.
Desai MP, Colaco MP, Ajgaonkar AR, Mahadik CV, Vas FE, Rege C, et al: Neonatal screening for congenital hypothyroidism in a developing country: problems and strategies. Indian Y Pediatr 1987;54:571–581.
23.
Azizi F, Sheikholeslam R, Hedayati M, Mirmiran P, Malekafzali H, Kimiagar M, et al: Sustainable control of iodine deficiency in Iran: beneficial result of the implementation of the mandatory law on salt iodization. J Endocrinol Invest 2009:23:409–413.
24.
Hashemipoor M, Amini M, Gheisari A, Salarifar S, Iranpour R, Aminoroaya A: Comparison of urinary iodine exertion in neonates and their mothers in Isfahan, Iran. Endocr Pract 2002;8:347–350.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.